c3 polymorphism in hyperlipoproteinemia (hlp)

c3 polymorphism in lymphosarcoma and hodgkin disease

the c3 phenotypes were determined by high-voltage agarose gel electrophoreses in german patients suffering from lymphosarcoma (n=34), hodgkin (n=59) and a group of other haematological diseases (n=46). frequencies of c3 ss, sf and ff pho=enotypes were not significantly different from the frequencies found in a control group of 322 healthy germans. however, high frequency of the ff phenotype in ...

EcoRI polymorphism in the human third complement component (C3) gene.

Source/Description A cDNA fragment, pC3.11 (1) was used as probe. Polymorphisms: EcoRI cleavage of genomic DNA reveals a 2 allele polymorphism with band sizes of 5.2 and 5.6 kb. Invariant bands of 11.5, 11.0, 9.0 and 3 0 kb were also present. Frequency: Estimated from 35 unrelated Caucasians. Allele Frequency Dl 5.2 0.67 D2 5.6 0.33 Chromosomal Localisation: The human C3 gene had been assigned ...

C3 R102G polymorphism increases risk of age-related macular degeneration.

Inflammation has long been suspected to play a role in the pathogenesis of age-related macular degeneration (AMD). Association of variants in the complement factor H (CFH) and complement factor B (CFB) genes has targeted the search for additional loci to the alternative complement cascade, of which C3 is a major component. Two non-synonymous coding polymorphisms within C3, R102G and L314P, have...

Diabetes mellitus in familial hyperlipoproteinemia.

The relationship between a certain form of type 2 diabetes mellitus and familial endogenous hyperlipoproteinemia still remains confused. Therefore, we examined glucose tolerance and insulin secretion in 133 members (6-80 years old) of 15 families with a history of endogenous hyperlipoproteinemia. A segregation study was carried out to compare the prevalence of diabetes in hyperlipoproteinemic a...

Erythrocyte Antioxidant Enzymes in Hyperlipoproteinemia

Pathogenesis of hyperlipoproteinemia.

In the past 25 years, great advances have been made in our understanding of lipoprotein metabolism and of the causation of hyperlipidemia. These advances have been due in part to the study of patients with unusual defects in lipoprotein metabolism. Follow-up investigations into the specific metabolic defects in these patients have revealed qualitative abnormalities in the structure and function...